AbCellera Biologics Inc. (ABCL): Price and Financial Metrics
ABCL Price/Volume Stats
| Current price | $5.02 | 52-week high | $10.59 |
| Prev. close | $4.91 | 52-week low | $3.87 |
| Day low | $4.86 | Volume | 899,900 |
| Day high | $5.08 | Avg. volume | 1,363,759 |
| 50-day MA | $5.29 | Dividend yield | N/A |
| 200-day MA | $5.67 | Market Cap | 1.46B |
ABCL Stock Price Chart Interactive Chart >
ABCL POWR Grades
- ABCL scores best on the Value dimension, with a Value rank ahead of 72.6% of US stocks.
- The strongest trend for ABCL is in Growth, which has been heading up over the past 26 weeks.
- ABCL's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).
ABCL Stock Summary
- Price to trailing twelve month operating cash flow for ABCL is currently 248.87, higher than 98.87% of US stocks with positive operating cash flow.
- ABCL's price/sales ratio is 32.82; that's higher than the P/S ratio of 95.69% of US stocks.
- Revenue growth over the past 12 months for ABCELLERA BIOLOGICS INC comes in at -91.65%, a number that bests merely 1.44% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to ABCELLERA BIOLOGICS INC are INMB, RGTI, HLTH, MTNB, and SWKS.
- To check out ABCELLERA BIOLOGICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001703057.
ABCL Valuation Summary
- ABCL's price/sales ratio is 32.9; this is 1395.45% higher than that of the median Healthcare stock.
- Over the past 37 months, ABCL's EV/EBIT ratio has gone up 7771.6.
Below are key valuation metrics over time for ABCL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ABCL | 2023-12-29 | 32.9 | 1.4 | -12.8 | -10.0 |
| ABCL | 2023-12-28 | 34.1 | 1.5 | -13.3 | -10.5 |
| ABCL | 2023-12-27 | 33.4 | 1.4 | -13.0 | -10.2 |
| ABCL | 2023-12-26 | 33.2 | 1.4 | -13.0 | -10.2 |
| ABCL | 2023-12-22 | 32.8 | 1.4 | -12.8 | -10.0 |
| ABCL | 2023-12-21 | 32.8 | 1.4 | -12.8 | -10.0 |
ABCL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ABCL has a Quality Grade of C, ranking ahead of 74.92% of graded US stocks.
- ABCL's asset turnover comes in at 0.453 -- ranking 98th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ABCL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.453 | 1 | 1.811 |
ABCL Price Target
For more insight on analysts targets of ABCL, see our ABCL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $45.40 | Average Broker Recommendation | 1.3 (Strong Buy) |
AbCellera Biologics Inc. (ABCL) Company Bio
AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics. It was founded in 2012 and headquartered in Vancouver, British Columbia.
Latest ABCL News From Around the Web
Below are the latest news stories about ABCELLERA BIOLOGICS INC that investors may wish to consider to help them evaluate ABCL as an investment opportunity.
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024VANCOUVER, British Columbia, December 20, 2023--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). |
AI Meets Biotech: 3 Top Stocks Transforming Medical ScienceThe AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. |
16 Best Penny Stocks To Buy For 2024In this article, we will take a detailed look at the 16 Best Penny Stocks To Buy For 2024. For a quick overview of such stocks, read our article 5 Best Penny Stocks To Buy For 2024. The stock market’s optimism wave recently saw a break after latest data showed that the US labor market remains resilient despite […] |
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In NovemberThe AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. |
AbCellera Biologics Insiders Added US$2.47m Of Stock To Their HoldingsOver the last year, a good number of insiders have significantly increased their holdings in AbCellera Biologics Inc... |
ABCL Price Returns
| 1-mo | -12.08% |
| 3-mo | 24.26% |
| 6-mo | -12.85% |
| 1-year | -51.82% |
| 3-year | -88.85% |
| 5-year | N/A |
| YTD | -12.08% |
| 2023 | -43.63% |
| 2022 | -29.16% |
| 2021 | -64.46% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...